… , which is considered a PARP inhibitor. Now, PARP inhibitors are something that … you could qualify for a PARP inhibitor. Now, with all that … the patients qualify for a PARP inhibitor in this study. What …

… developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor … of advancing our novel PARP/Wnt inhibitor through … numerous cancers. By inhibiting PARP and blocking Wnt pathway … of stenoparib, a novel PARP/tankyrase inhibitor for …

… and the integration of PARP inhibitors like olaparib, in … to neutropenia and infections. PARP Inhibitors With Endocrine Therapy … these patients. Olaparib, a PARP inhibitor, addresses this need … improve treatment outcomes and PARP inhibitors benefit subsets of …

… , or AKT pathway inhibitors or PARP inhibition, or other investigational agents …

… as poly (ADP-ribose) polymerase (PARP) inhibitors. We have some data … to become more sensitive to PARP inhibitors because they are suppressed …

… a group of drugs called PARP inhibitors. In 2023, the … by blocking a protein called PARP, which normally provides an alternative … route for DNA repair. Blocking PARP makes it harder for HRR … initial treatment followed by a PARP inhibitor if the cancer started …

… for poly (ADP-ribose) polymerases (PARP) inhibitors (talazoparib) therapy.39 Among …

… poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. This phase 2 trial …

… and her role in developing PARP inhibitors. She is the executive …

… the combination of stenoparib, a PARP inhibitor, with the chemotherapy agent …